MiA outcome by laboratory and clinical variables
| Patient characteristics . | Patients with MiA . | Patients without MiA . | P . |
|---|---|---|---|
| Continuous variables, mean (SD) | |||
| Age (y) | 13.2 (4.4) | 13.9 (4.4) | .3 |
| Systolic blood pressure (mm Hg) | 118.5 (10.7) | 117.4 (10.6) | .6 |
| Diastolic blood pressure (mm Hg) | 63.8 (7.5) | 62.9 (7.1) | .5 |
| Hb (g/dL) | 8.3 (1.4) | 9.1 (1.5) | .003* |
| Fetal Hb (%) | 6.7 (7.7) | 10.1 (8.9) | .03* |
| MCV (fL) | 88.1 (7.7) | 87.9 (10.8) | .9 |
| ARC (×109/L) | 510 (220) | 380 (190) | .007* |
| WBC count (×109/L) | 13.5 (5.2) | 10.1 (3.6) | <.0001* |
| ANC (×109/L) | 7.6 (4.1) | 5.1 (2.6) | .001* |
| Platelet count (×109 /L) | 418 (125) | 387 (134) | .2 |
| eGFR (mL/min per 1.73 m2)† | 163.1 (34.2) | 168.3 (40.2) | .5 |
| Maximum eGFR (mL/min per 1.73 m2)§ | 169.4 (35.1) | 173.7 (35.3) | .5 |
| Bilirubin (mg/dL) | 4.2 (2.9) | 3.1 (1.9) | .02* |
| Categorical variables, count/total (%total) | |||
| Sex | |||
| Female | 27/75 (36%) | 48/75 (64%) | .3 |
| Male | 22/77 (29%) | 55/77 (71%) | |
| Disease-modifying therapy | |||
| No therapy (n = 24) | 10 (42%) | 14 (56%) | .2 |
| Transfusion (n = 53) | 20 (38%) | 33 (62%) | |
| Hydroxyurea (n = 75) | 19 (25%) | 56 (75%) | |
| Continuous variables, mean (SD) among patients on hydroxyurea | |||
| Dose (mg/kg) | 25.2 (3.6) | 24.5 (3.2) | .5 |
| HbF% | 8.4 (5.8) | 14.3 (8.5) | <.001* |
| MCV (fL) | 91.3 (8.7) | 93.8 (11.5) | .3 |
| Patient characteristics . | Patients with MiA . | Patients without MiA . | P . |
|---|---|---|---|
| Continuous variables, mean (SD) | |||
| Age (y) | 13.2 (4.4) | 13.9 (4.4) | .3 |
| Systolic blood pressure (mm Hg) | 118.5 (10.7) | 117.4 (10.6) | .6 |
| Diastolic blood pressure (mm Hg) | 63.8 (7.5) | 62.9 (7.1) | .5 |
| Hb (g/dL) | 8.3 (1.4) | 9.1 (1.5) | .003* |
| Fetal Hb (%) | 6.7 (7.7) | 10.1 (8.9) | .03* |
| MCV (fL) | 88.1 (7.7) | 87.9 (10.8) | .9 |
| ARC (×109/L) | 510 (220) | 380 (190) | .007* |
| WBC count (×109/L) | 13.5 (5.2) | 10.1 (3.6) | <.0001* |
| ANC (×109/L) | 7.6 (4.1) | 5.1 (2.6) | .001* |
| Platelet count (×109 /L) | 418 (125) | 387 (134) | .2 |
| eGFR (mL/min per 1.73 m2)† | 163.1 (34.2) | 168.3 (40.2) | .5 |
| Maximum eGFR (mL/min per 1.73 m2)§ | 169.4 (35.1) | 173.7 (35.3) | .5 |
| Bilirubin (mg/dL) | 4.2 (2.9) | 3.1 (1.9) | .02* |
| Categorical variables, count/total (%total) | |||
| Sex | |||
| Female | 27/75 (36%) | 48/75 (64%) | .3 |
| Male | 22/77 (29%) | 55/77 (71%) | |
| Disease-modifying therapy | |||
| No therapy (n = 24) | 10 (42%) | 14 (56%) | .2 |
| Transfusion (n = 53) | 20 (38%) | 33 (62%) | |
| Hydroxyurea (n = 75) | 19 (25%) | 56 (75%) | |
| Continuous variables, mean (SD) among patients on hydroxyurea | |||
| Dose (mg/kg) | 25.2 (3.6) | 24.5 (3.2) | .5 |
| HbF% | 8.4 (5.8) | 14.3 (8.5) | <.001* |
| MCV (fL) | 91.3 (8.7) | 93.8 (11.5) | .3 |
eGFR, estimated glomerular filtration rate; HbF%, percent fetal hemoglobin; MCV, mean corpuscular volume; SD, standard deviation.
P < .05 defined as statistically significant.
Glomerular filtration rate was estimated by serum cystatin C (eGFR) using BN ProSpec System: log GFR = 1.962 + [1.123 × log (1/cystatin C)].
Maximum eGFR obtained from highest eGFR among all recorded eGFR measurements obtained prior to developing MiA or participants’ last clinic visit.